Molecular predictors of response to chemotherapy in non-small cell lung cancer

Cancer Journal

Volumn 17, Issue 2, 2011, Pages 104-113

  Andrews, Jenny ^a   Yeh, Paul ^b   Pao, William ^c   Horn, Leora ^c  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

biomarkers; ERCC1; Lung cancer; molecular mechanisms; RRM1; TS

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ECOG 4599; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; RIBONUCLEOTIDE REDUCTASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULAR MECHANICS; PREDICTION; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 79954550873     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318213f3cf     Document Type: Review

References (84)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer [review]. N Engl J Med. 2008;359:1367-1380.
3. Visbal AL, Leighl NB, Feld R, et al. Adjuvant chemotherapy for earlystage non-small cell lung cancer. Chest. 2005;128:2933-2943. (Pubitemid 41507653)
4. Pao W, Lafrate AJ, Su Z. Genetically informed lung cancer medicine. J Pathol. 2011;223:230-240.
5. Pao W, Chmielecki J. Rationale, biologically based treatment of EGFRmutant non-small-cell lung cancer. Nat Rev Cancer. 2010;10:760-774.
6. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175-180.
7. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;15:4-9.
8. Ikeda N, Nagase S, Ohira T. Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers [review]. Ann Thorac Cardiovasc Surg. 2009;15:144-149.
9. Mountain CF. Surgical treatment of lung cancer: past and present. Methods Mol Med. 2003;75:453-487.
10. Scagliotti G, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small cell lung cancer. J Natl Cancer Inst. 2003;95:1453-1461. (Pubitemid 37279330)
11. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26:173-182. (Pubitemid 38759943)
12. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New Engl J Med. 2004;350:351-360. (Pubitemid 38101630)
13. Douillard JY, Rossell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IBYIIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719-727. (Pubitemid 44283661)
14. Winton TL, Livingston R, Johnson D, et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR [abstract]. J Clin Oncol. 2004;22:7018
15. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311: 899-909.
16. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552-3559.
17. Schiller J, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002;346:92-98. (Pubitemid 34438899)
18. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell. J Clin Oncol. 2008;26:3543-3551.
19. GrLnberg BH, Bremnes RM, FlLtten O, et al. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:3217-3224.
20. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432-1440.
21. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22: 2184-2191. (Pubitemid 41095154)
22. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355: 2542-2550. (Pubitemid 44917502)
23. Wagstaff AJ, Keam SJ, McCormack PL. Bevacizumab plus platinumbased chemotherapy: in advanced non-small cell lung cancer. BioDrugs. 2009;23:187-196.
24. Vilmar AC, Santoni-Rugiu E, SLrenson JB. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol. 2010;21:1817-1824.
25. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005;127:978-983. (Pubitemid 40775532)
26. Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res. 2004;10:4215s.
27. Takezawa K, Okamoto I, Tsukioka S, et al. Identification of thymidylate synthase as a potential therapeutic target for lung cancer. Br J Cancer. 2010;103:354-361.
28. Hoejimakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411:366-374.
29. Yu D, Zhang X, Liu J, et al. Characterization of functional excision repair cross complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res. 2008;14: 2878-2886.
30. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1:22-33. (Pubitemid 33741878)
31. Gazdar AF. DNA repair and survival in lung cancerVthe two faces of Janus. N Engl J Med. 2007;356:771-773. (Pubitemid 46294609)
32. Fisseler-Eckhoff A. Prognostic factors in histopathology of lung cancer. Front Radiat Ther Oncol. 2010;42:1-14.
33. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-991. (Pubitemid 44343542)
34. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci. 1995;20:435-439.
35. Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst. 1996;88:1346-1360. (Pubitemid 26329752)
36. Lee KB, Parker RJ, Bohr V, et al. Cisplatin sensitivity/resistance in UV repairYdeficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis. 1993;14:2177-2180. (Pubitemid 23311452)
37. Dabholkar M, Vionnet J, Bostick-Bruton F, et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Investig. 1994;94:703-708. (Pubitemid 24251002)
38. Li Q, Yu JJ, Mu C, et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cells. Anticancer Res. 2000;20:645-652. (Pubitemid 30240614)
39. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8: 2286-2291. (Pubitemid 34753602)
40. Okuda K, Sasaki H, Dumontet C, et al. Expression of excision repair cross-complementation group 1 and class III A-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer. 2008;62:105-112.
41. Hwang IG, Ahn MJ, Park BB, et al. ERCC1 expression as a predictive marker in stage IIIA, N2 positive non-small lung cancer patients treated with neoadjuvant concurrent chemoradiotherapy followed by surgery. J Thorac Oncol. 2007;S4:S367.
42. Azuma K, Komohara Y, Sasada T, et al. Excision repair crosscomplementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci. 2007;98:1336-1343. (Pubitemid 47241754)
43. Ota S, Ishii G, Goto K, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer. 2009;64:98-104.
44. Available at: http://www.clinicaltrials.gov. Accessed December 21, 2010.
45. Lee HW, Choi YW, Han JH, et al. Expression of excision repair crosscomplementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer. 2009;65:377-382.
46. Booton R, Ward T, Ashcroft L, et al. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol. 2007;2:902-906. (Pubitemid 47511592)
47. Wachters FM,Wong LS, TimensW, et al. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer. 2005; 50:211-219.
48. Wang X, Zhao J, Yang L, et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol. 2010;27:484-490.
49. Su C, Zhou S, Zhang L, et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol. 2010.
50. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006;107: 1589-1596. (Pubitemid 44546920)
51. Holm B, Mellemgaard A, Skov T, et al. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol. 2009;27:4254-4259.
52. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross complementing 1 mRNA expression: a phase III trial in non small cell lung cancer. J Clin Oncol. 2007;25: 2747-2754. (Pubitemid 47123183)
53. Bepler G, Gautam A, McIntyre LM, et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in nonsmall cell lung cancer. J Clin Oncol. 2002;20:1353-1360. (Pubitemid 34177442)
54. Souglakos J, Boukovinas I, Taron M, et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer. 2008;98:1710-1715. (Pubitemid 351684679)
55. Pitterle DM, Kim YC, Jolicoeur EM, et al. Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). Mamm Genome. 1999;10:916-922. (Pubitemid 29445383)
56. Davidson JD, Ma L, Flagella M, et al. An increase in expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 2004;64: 3761-3766. (Pubitemid 38697284)
57. Gautam A, Bepler G. Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res. 2006;66: 6497-6502. (Pubitemid 44085603)
58. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007;356:800-808. (Pubitemid 46294612)
59. Mini E, et al. Cellular pharmacology of gemcitabine. Ann Oncol. 2006; 17[suppl 5]:v7-v12. (Pubitemid 43994854)
60. Toschi L, Cappuzzo F. Gemcitabine for the treatment of advanced nonsmall cell lung cancer. Oncol Targets Ther. 2009;2:209-217.
61. Rosell R, Scaglioti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three arm randomized trial in metastatic lung cancer. Oncogene. 2003;22:3548-3553. (Pubitemid 36765314)
62. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatinYtreated advanced non-small cell lung cancer patients. Clin Cancer Res. 2004;10: 1318-1325. (Pubitemid 38365223)
63. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced nonsmall cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006;17:1818-1825. (Pubitemid 44884058)
64. Lee JJ, Maeng CH, Baek SK, et al. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2010;70:205-210.
65. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vivo and in vitro efficacy of gemcitabine and platinum in non small cell lung cancer. J Clin Oncol. 2006;24:4731-4737. (Pubitemid 46646245)
66. Reynolds C, Obasaju C, Schell MJ, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 2009;27:5808-5815.
67. Zeng L, Ou G, Itasaka S, et al. TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci. 2008;99:2327-2335.
68. Pestalozzi BC, McGinn CJ, Kinsella TJ, et al. Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. Br J Cancer. 1995;71:1151-1157.
69. Chu E, Copur SM, Ju J, et al. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol. 1999; 19:1582-1594. (Pubitemid 29046899)
70. Lenz HJ, Leichman CJ, Danenberg KD, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and OS. J Clin Oncol. 1996;14:176-182. (Pubitemid 26020011)
71. Huang CL, Yokomise H, Koboyashi S, et al. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FUYbased chemotherapy. Int J Oncol. 2000;17:47-54.
72. Peters JG, van der Wilt CL, van Triest B, et al. Thymidylate synthase and drug resistance. Eur J Cancer. 1995;31A:1299-1305.
73. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330-338. (Pubitemid 37328853)
74. Volm M, Mattern J. Elevated expression of thymidylate synthase in doxorubicin resistant human non small cell lung carcinomas. Anticancer Res. 1992;12:2293-2296. (Pubitemid 23105448)
75. Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol. 2005;23:4999-5006. (Pubitemid 46224006)
76. Ishihama H, Chida M, ArakiO, et al. Comparison of 5-fluorouracilYrelated gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. Jpn J Clin Oncol. 2009;39:33-36.
77. Nakagawa T, Tanaka F, Otake Y, et al. Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer. 2002;35:165-170. (Pubitemid 34136094)
78. Grimminger PP, Schneider PM, Metzger R, et al. Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected nonsmall- cell lung cancer. Clin Lung Cancer. 2010;11:328-334.
79. Hashimoto H, Ozeki Y, Sato M, et al. Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer. 2006;106:1595-1601.
80. Zheng Z, Li X, Schell MJ, et al. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer. 2008;112:2765-2773. (Pubitemid 351969222)
81. Ozasa H, Oguri T, Uemura T, et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci. 2010;101: 161-166.
82. Wu MF, Hsiao YM, Huang CF, et al. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. J Thorac Oncol. 2010;5:1143-1151.
83. Scagliotti G, Hanna N, Fosella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14:253-263.
84. Camp RL, Chung GG, Rimm DL, et al. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8:1323-1328.